Description
Release form
Injection.
Packing
10 pcs.
Pharmacological action
Pharmacodynamics
High molecular weight mucopolysaccharide, affecting metabolic processes in hyaline cartilage. Reduces degenerative changes in the cartilage tissue of joints, accelerates its recovery processes, stimulates the synthesis of proteoglycans. During treatment with the drug, pain decreases and the mobility of the affected joints improves.
In the treatment of degenerative joint changes with the development of secondary synovitis, a positive effect can be observed already 2-3 weeks after the start of the drug: joint pain decreases, the clinical manifestations of reactive synovitis disappear, and the range of motion in the affected joints increases. The therapeutic effect persists for a long time after the end of the course of treatment. Mika
Pharmacokinetics
After intramuscular administration of chondroitin, sulfate is rapidly distributed. Already 30 minutes after the injection, it is detected in the blood in significant concentrations. The maximum concentration (Cmax) of chondroitin sulfate in plasma is reached after 1 h, then gradually decreases over 2 days.
Chondroitin sulfate accumulates mainly in the cartilage of the joints. The synovial membrane is not an obstacle to the penetration of the drug into the joint cavity. It was shown in experiments that 15 minutes after intramuscular injection of chondroitin sulfate is detected in the synovial fluid, then penetrates into the articular cartilage, where its Cmax is reached after 48 hours.
Indications
Degenerative degenerative diseases of the joints and spine: peripheral joint osteoarthritis
intervertebral osteochondrosis and
osteoarthritis to accelerate the formation of bone marrow in fractures.
Contraindications
Hypersensitivity to the drug or its components
bleeding and bleeding tendency
thrombophlebitis
childhood
pregnancy and lactation (there are currently no data on the safety of the drug).
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
Pediatric use
Data on the efficacy and safety of chondroitin sulfate in children are currently not available.
Composition
1 ml injection contains:
Active substance: chondroitin sodium sulfate – 100 mg.
Excipients: benzyl alcohol – 9 mg, sodium disulfite – 1 mg, sodium hydroxide – up to pH 6.0-7.5, water d / i – up to 1 ml.
Dosing and Administration
The drug is administered intramuscularly at 100 mg every other day.
With good tolerance, the dose is increased to 200 mg, starting with the fourth injection.
The course of treatment is 25-30 injections. If necessary, after 6 months, a second course of treatment is possible.
For the formation of bone marrow, the course of treatment is 3-4 weeks (10-14 injections every other day).
Side effects
Allergic reactions: pruritus, erythema, urticaria, dermatitis, hemorrhage at the injection site.
Drug interaction
It is possible to enhance the action of indirect anticoagulants, antiplatelet agents, fibrinolytics, which requires more frequent monitoring of blood coagulation when used together.
Storage Conditions
Store in a dark place at a temperature not exceeding 25 ° C.
Expiration
2 years.
active substance
Chondroitin sulfate
Terms leave through pharmacies
In retseptu
lekarstvennaja form
Solution for
